ArticleBreast cancer research : BCR2025
The role and prognostic value of mitochondria-related gene PARK7 in breast cancer.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A powerful representation learning method for enhanced analysis of incomplete multi-omics data.NPJ systems biology and applications · 2026Article
- HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4.Journal of cancer research and clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBreast cancer is the most common malignant tumor among women globally, with incidence and mortality rates ranking first among female cancers. Mitochondrial dysfunction plays a crucial role in the occurrence, development, and metastasis of breast cancer, but the specific mechanisms remain unclear. This study aims to explore the mechanisms and prognostic value of the mitochondrial-related gene PARK7 in breast cancer.
methodsThis study integrated summary data on the methylation levels, expression levels, and protein abundance of mitochondrial-related genes. The discovery phase data were sourced from the IEU GWAS database, while the validation phase data came from the FinnGen study dataset. Mendelian randomization and colocalization analyses were conducted to explore the potential associations between the methylation, expression, and protein abundance of mitochondrial-related genes and breast cancer risk. Clinical and pathological data, as well as gene expression data from breast cancer patients, were obtained from the TCGA database. Cox regression analysis was used to assess the relationship between PARK7 expression and clinical pathological features, and a prognostic model was constructed. Additionally, in vitro experiments were performed to verify the effects of PARK7 on triple-negative breast cancer cells.
resultsThe study found that high expression of the PARK7 gene is closely related to a reduced risk of breast cancer (OR 0.91, 95% Cl 0.88-0.95; PPH4 = 0.90), which was also validated in the FinnGen dataset. Patients with high PARK7 expression had longer survival times and higher survival probabilities in the TCGA database. In vitro experiments showed that overexpression of PARK7 significantly inhibited the proliferation, migration, and colony formation of triple-negative breast cancer cells, while promoting apoptosis and significantly increasing mitochondrial membrane potential, indicating altered mitochondrial function. Furthermore, Western blot analysis revealed that overexpression of PARK7 led to increased PTEN protein expression and decreased p-PI3K and p-AKT protein expression, suggesting that PARK7 may exert its tumor-suppressive effects by modulating the PI3K/Akt signaling pathway.
conclusionHigh expression of the PARK7 gene is closely related to reduced breast cancer risk and good prognosis, and it may exert its tumor-suppressive effects by regulating the expression of apoptosis-related proteins and migration-related proteins, as well as by affecting mitochondrial function and modulating the PI3K/Akt signaling pathway. It can serve as a potential biomarker for the diagnosis, treatment, and prognosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.